Stereotactic Body Radiation Therapy for Stage I Non-small Cell Lung Cancer

Overview

Journal Thorac Surg Clin

Publisher Elsevier

Specialties General Surgery
Pulmonary Medicine

Date 2007 Jul 14

PMID 17626403

Citations 16

Authors

Joe Y Chang

Jack A Roth

Affiliations

Soon will be listed here.

Abstract

Image-guided SBRT with the delivery of a BED greater than 100 Gy is feasible and safe in the treatment of peripherally located inoperable stage I NSCLC. The 3- to 5-year local control and overall survival rates for SBRT seem to be much better than the rates for conventional radiotherapy, and the toxicity rate is minimal. Particularly for stage Ia (T1N0M0) disease, survival rates with SBRT were comparable with rates seen with surgical resection. SBRT is becoming the standard treatment for inoperable stage I NSCLC. Its role in operable stage I NSCLC. however. is not clear. To balance improved targeting accuracy with minimized treatment-related toxicity. a reliable immobilization device and consideration of image-guided tumor motion are crucial. The optimal dose regimen remains unclear, but a BED greater than 100 Gy seems warranted.

Citing Articles

Development of Radiographic Radiation Pneumonitis (RP) in Non-small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy (SBRT) May Be Protective Against Further Disease Progression.

Wolf C, Wesolowski M, Stang K, Alite F, Harkenrider M Cureus. 2022; 14(6):e25994.

PMID: 35859984 PMC: 9288130. DOI: 10.7759/cureus.25994.

Safety and efficacy of thermal ablation for subpleural lung cancers.

Cao F, Xie L, Qi H, Chen S, Shen L, Song Z Thorac Cancer. 2019; 10(6):1340-1347.

PMID: 31020801 PMC: 6558492. DOI: 10.1111/1759-7714.13068.

Surgical Resection Versus Stereotactic Body Radiation Therapy for Stage I NSCLC: Can Randomized Trials Provide the Solution?.

Subramanian M, Meyers B Cancers (Basel). 2018; 10(9).

PMID: 30181523 PMC: 6162523. DOI: 10.3390/cancers10090310.

Evaluation of ray tracing and Monte Carlo algorithms in dose calculation and clinical outcomes for robotic stereotactic body radiotherapy of lung cancers.

Braunstein S, Dionisio S, Lometti M, Pinnaduwage D, Chuang C, Yom S J Radiosurg SBRT. 2018; 3(1):67-79.

PMID: 29296387 PMC: 5725332.

Survival and prognostic factors of non-small cell lung cancer patients with postoperative locoregional recurrence treated with radical radiotherapy.

Ma L, Qiu B, Zhang J, Li Q, Wang B, Zhang X Chin J Cancer. 2017; 36(1):93.

PMID: 29228994 PMC: 5725840. DOI: 10.1186/s40880-017-0261-0.